APP and Alzheimer disease: The overexpression of C/EBPβ in an AD mouse model accelerates the onset of AD-like pathogenesis and worsens cognitive dysfunctions, while a reduction in C/EBPβ expression decreases the expression of δ-secretase, APP and tau and reverses both amyloid and tau pathology and cognitive impairments.